vs
Side-by-side financial comparison of NU SKIN ENTERPRISES, INC. (NUS) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
NU SKIN ENTERPRISES, INC. is the larger business by last-quarter revenue ($320.6M vs $177.4M, roughly 1.8× Pacira BioSciences, Inc.). Pacira BioSciences, Inc. runs the higher net margin — 1.6% vs 0.6%, a 1.1% gap on every dollar of revenue. On growth, Pacira BioSciences, Inc. posted the faster year-over-year revenue change (5.0% vs -12.0%). Over the past eight quarters, Pacira BioSciences, Inc.'s revenue compounded faster (-0.2% CAGR vs -14.5%).
Nu Skin Enterprises, Inc. is an American multilevel marketing company that develops and sells personal care products and dietary and nutritional supplements. Under the Nu Skin and Pharmanex brands, the company sells its products in 54 markets through a network of approximately 1.2 million independent distributors.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
NUS vs PCRX — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $320.6M | $177.4M |
| Net Profit | $1.8M | $2.9M |
| Gross Margin | 66.9% | — |
| Operating Margin | 34.4% | 3.9% |
| Net Margin | 0.6% | 1.6% |
| Revenue YoY | -12.0% | 5.0% |
| Net Profit YoY | — | — |
| EPS (diluted) | $0.04 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $320.6M | $177.4M | ||
| Q4 25 | $370.3M | $196.9M | ||
| Q3 25 | $364.2M | $179.5M | ||
| Q2 25 | $386.1M | $181.1M | ||
| Q1 25 | $364.5M | $168.9M | ||
| Q4 24 | $445.6M | $187.3M | ||
| Q3 24 | $430.1M | $168.6M | ||
| Q2 24 | $439.1M | $178.0M |
| Q1 26 | $1.8M | $2.9M | ||
| Q4 25 | $14.5M | — | ||
| Q3 25 | $17.1M | $5.4M | ||
| Q2 25 | $21.1M | $-4.8M | ||
| Q1 25 | $107.5M | $4.8M | ||
| Q4 24 | $-36.1M | — | ||
| Q3 24 | $8.3M | $-143.5M | ||
| Q2 24 | $-118.3M | $18.9M |
| Q1 26 | 66.9% | — | ||
| Q4 25 | 70.7% | 79.5% | ||
| Q3 25 | 70.5% | 80.9% | ||
| Q2 25 | 68.8% | 77.4% | ||
| Q1 25 | 67.8% | 79.7% | ||
| Q4 24 | 62.7% | 78.7% | ||
| Q3 24 | 70.1% | 76.9% | ||
| Q2 24 | 70.0% | 75.1% |
| Q1 26 | 34.4% | 3.9% | ||
| Q4 25 | 6.3% | 1.2% | ||
| Q3 25 | 5.9% | 3.5% | ||
| Q2 25 | 8.0% | 4.7% | ||
| Q1 25 | -2.7% | 1.2% | ||
| Q4 24 | -11.9% | 13.2% | ||
| Q3 24 | 4.2% | -82.8% | ||
| Q2 24 | -28.6% | 15.9% |
| Q1 26 | 0.6% | 1.6% | ||
| Q4 25 | 3.9% | — | ||
| Q3 25 | 4.7% | 3.0% | ||
| Q2 25 | 5.5% | -2.7% | ||
| Q1 25 | 29.5% | 2.8% | ||
| Q4 24 | -8.1% | — | ||
| Q3 24 | 1.9% | -85.1% | ||
| Q2 24 | -26.9% | 10.6% |
| Q1 26 | $0.04 | $0.07 | ||
| Q4 25 | $0.27 | $0.05 | ||
| Q3 25 | $0.34 | $0.12 | ||
| Q2 25 | $0.43 | $-0.11 | ||
| Q1 25 | $2.14 | $0.10 | ||
| Q4 24 | $-0.73 | $0.38 | ||
| Q3 24 | $0.17 | $-3.11 | ||
| Q2 24 | $-2.38 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $198.7M | $144.3M |
| Total DebtLower is stronger | $223.6M | — |
| Stockholders' EquityBook value | $794.1M | $653.9M |
| Total Assets | $1.4B | $1.2B |
| Debt / EquityLower = less leverage | 0.28× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $198.7M | $144.3M | ||
| Q4 25 | $239.8M | $238.4M | ||
| Q3 25 | $253.0M | $246.3M | ||
| Q2 25 | $265.4M | $445.9M | ||
| Q1 25 | $213.6M | $493.6M | ||
| Q4 24 | $198.0M | $484.6M | ||
| Q3 24 | $237.8M | $453.8M | ||
| Q2 24 | $232.9M | $404.2M |
| Q1 26 | $223.6M | — | ||
| Q4 25 | — | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | — | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $794.1M | $653.9M | ||
| Q4 25 | $805.2M | $693.1M | ||
| Q3 25 | $799.8M | $727.2M | ||
| Q2 25 | $787.8M | $757.8M | ||
| Q1 25 | $754.0M | $798.5M | ||
| Q4 24 | $651.5M | $778.3M | ||
| Q3 24 | $706.9M | $749.6M | ||
| Q2 24 | $686.2M | $879.3M |
| Q1 26 | $1.4B | $1.2B | ||
| Q4 25 | $1.4B | $1.3B | ||
| Q3 25 | $1.4B | $1.3B | ||
| Q2 25 | $1.4B | $1.5B | ||
| Q1 25 | $1.4B | $1.6B | ||
| Q4 24 | $1.5B | $1.6B | ||
| Q3 24 | $1.6B | $1.5B | ||
| Q2 24 | $1.6B | $1.6B |
| Q1 26 | 0.28× | — | ||
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NUS
Segment breakdown not available.
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
